PriceTargets.com logo

Tempest Therapeutics - TPST Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.25
  • Forecasted Upside: 550.58%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.42 As of 04/23/2024 01:00 AM ET
▲ +0.18 (5.56%)

This chart shows the closing price for TPST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tempest Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TPST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TPST

Analyst Price Target is $22.25
▲ +550.58% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Tempest Therapeutics in the last 3 months. The average price target is $22.25, with a high forecast of $47.00 and a low forecast of $13.00. The average price target represents a 550.58% upside from the last price of $3.42.

This chart shows the closing price for TPST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Tempest Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/20/2024William BlairReiterated RatingOutperformLow
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$47.00Low
3/14/2024ScotiabankInitiated CoverageSector Outperform$13.00Low
2/8/2024Jefferies Financial GroupInitiated CoverageBuy$15.00Low
10/11/2023HC WainwrightBoost TargetBuy ➝ Buy$35.00 ➝ $47.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00Low
4/28/2023LADENBURG THALM/SH SHBoost Target$8.00 ➝ $14.00Low
3/23/2023Piper SandlerLower TargetOverweight$10.00 ➝ $6.00Low
3/23/2023HC WainwrightReiterated RatingBuy$35.00Low
2/8/2023HC WainwrightReiterated RatingBuy$35.00Low
11/8/2022William BlairReiterated RatingOutperformLow
9/15/2022LADENBURG THALM/SH SHInitiated CoverageBuy$8.00Low
5/27/2022HC WainwrightReiterated RatingBuy$35.00Low
5/13/2022Piper SandlerLower Target$20.00 ➝ $10.00Low
5/13/2022HC WainwrightLower Target$51.00 ➝ $35.00Low
10/21/2021William BlairInitiated CoverageOutperformMedium
8/13/2021HC WainwrightReiterated RatingBuy$51.00Low
7/13/2021HC WainwrightInitiated CoverageBuyHigh
7/6/2021Piper SandlerInitiated CoverageOverweight$23.00High
1/6/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$75.00 ➝ $30.00N/A
1/6/2021LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralN/A
8/12/2020WedbushReiterated RatingHold$45.00Low
6/14/2020SVB LeerinkReiterated RatingOutperform$75.00Medium
6/14/2020Roth CapitalReiterated RatingBuy$90.00Medium
5/29/2020CitigroupInitiated CoverageBuy$90.00High
5/21/2020OppenheimerReiterated RatingHold$30.00High
4/19/2020OppenheimerDowngradeOutperform ➝ Market PerformMedium
4/7/2020Roth CapitalLower Target$525.00 ➝ $90.00Medium
4/6/2020OppenheimerDowngradeOutperform ➝ Market Perform$375.00 ➝ $30.00High
4/6/2020WedbushDowngradeOutperform ➝ Neutral$375.00 ➝ $60.00High
3/24/2020CitigroupLower TargetBuy$345.00 ➝ $300.00Low
2/7/2020CitigroupInitiated CoverageBuy$345.00High
1/20/2020SVB LeerinkReiterated RatingOutperformMedium
1/10/2020Roth CapitalInitiated CoverageBuy$525.00High
9/16/2019Jefferies Financial GroupReiterated RatingBuy$330.00High
8/15/2019WedbushReiterated RatingBuy$360.00Low
8/13/2019OppenheimerLower TargetOutperform$390.00 ➝ $375.00Low
7/18/2019WedbushInitiated CoverageOutperform$360.00Low
7/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$390.00Medium
7/16/2019OppenheimerInitiated CoverageOutperform$390.00 ➝ $390.00High
7/15/2019CitigroupInitiated CoverageOutperform$390.00High
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 4 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/26/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 4 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
3/24/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Tempest Therapeutics logo
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Read More

Today's Range

Now: $3.42
Low: $3.24
High: $3.47

50 Day Range

MA: $3.74
Low: $3.10
High: $5.44

52 Week Range

Now: $3.42
Low: $0.17
High: $9.77

Volume

399,035 shs

Average Volume

958,659 shs

Market Capitalization

$75.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Tempest Therapeutics?

The following sell-side analysts have issued reports on Tempest Therapeutics in the last year: HC Wainwright, Jefferies Financial Group Inc., LADENBURG THALM/SH SH, Scotiabank, and William Blair.
View the latest analyst ratings for TPST.

What is the current price target for Tempest Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Tempest Therapeutics in the last year. Their average twelve-month price target is $22.25, suggesting a possible upside of 550.6%. HC Wainwright has the highest price target set, predicting TPST will reach $47.00 in the next twelve months. Scotiabank has the lowest price target set, forecasting a price of $13.00 for Tempest Therapeutics in the next year.
View the latest price targets for TPST.

What is the current consensus analyst rating for Tempest Therapeutics?

Tempest Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TPST will outperform the market and that investors should add to their positions of Tempest Therapeutics.
View the latest ratings for TPST.

What other companies compete with Tempest Therapeutics?

Other companies that are similar to Tempest Therapeutics include MediciNova, Assertio, Journey Medical, Anebulo Pharmaceuticals and Cue Biopharma. Learn More about companies similar to Tempest Therapeutics.

How do I contact Tempest Therapeutics' investor relations team?

Tempest Therapeutics' physical mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company's listed phone number is 415-798-8589 and its investor relations email address is [email protected]. The official website for Tempest Therapeutics is www.millendo.com. Learn More about contacing Tempest Therapeutics investor relations.